A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.

@article{Lindorfer2010ANA,
  title={A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.},
  author={Margaret A Lindorfer and Andrew W. Pawluczkowycz and Elizabeth Marie Peek and Kimberly Hickman and Ronald P Taylor and Charles J. Parker},
  journal={Blood},
  year={2010},
  volume={115 11},
  pages={
          2283-91
        }
}
The clinical hallmark of paroxysmal nocturnal hemoglobinuria (PNH) is chronic intravascular hemolysis that is a consequence of unregulated activation of the alternative pathway of complement (APC). Intravascular hemolysis can be inhibited in patients by treatment with eculizumab, a monoclonal antibody that binds complement C5 thereby preventing formation of the cytolytic membrane attack complex of complement. However, in essentially all patients treated with eculizumab, persistent anemia… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Adult Stem Cell Therapies: Alternatives to Plasticity

  • Stem Cell Biology and Regenerative Medicine
  • 2014
VIEW 24 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Complement in immune and inflammatory disorders: therapeutic interventions.

  • Journal of immunology
  • 2013
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 41 REFERENCES

The pathophysiology of paroxysmal nocturnal hemoglobinuria

CJ Parker
  • Exp Hematol
  • 2007